Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company in the U.S. that aims to develop and sell treatments for rare and chronic diseases affecting the nervous and muscular systems. Their product offerings include Firdapse and Ruzurgi, tablets designed to help patients with lambert-eaton myasthenic syndrome. Catalyst Pharmaceuticals, Inc. has also created partnerships with BioMarin Pharmaceutical Inc. and Endo Ventures Limited for the development and commercial distribution of other specialty medications.